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We report 3 cases of circumscribed choroidal hemangioma (CCH) effectively managed with intravitreal beva-
cizumab. One patient (case 1) who had recurrent CCH (1.6 mm in thickness) with prior laser photocoagulation was 
treated with intravitreal bevacizumab alone. Two patients (case 2 and 3) who had CCH (2.4 mm and 2.2 mm in 
thickness, respectively) with recent visual impairment were treated with bevacizumab followed by photodynamic 
therapy (PDT). Ophthalmic evaluations included visual acuity, ophthalmoscopic examination, fluorescein angio-
graphy, ultrasonography, and optical coherence tomography. Patients were followed up for 6-9 months. After 
therapy, all patients showed improved visual acuity due to complete resorption of subretinal fluid and macular 
edema. Ultrasonography demonstrated a reduction of the thickness of CCH in case 1 and complete regression of 
the lesions in case 2 and 3. No patient showed tumor recurrence. Intravitreal bevacizumab, alone or in combi-
nation therapy with PDT, may be a useful alternative for the treatment of symptomatic CCH with subretinal fluid.
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Circumscribed choroidal hemangioma (CCH) is an un-
common, benign vascular tumor manifesting as a discrete 
smooth, round, orange-red mass located posteriorly to the 
equator, mostly in the macular and peripapillary region.
1 
Although CCH is a benign lesion and is probably congenital, 
progressive enlargement and chronic exudation over decades 
may significantly compromise vision.
2 Intraretinal edema 
and accumulation of subretinal fluid affecting the macular 
area account for decreased vision in most patients.
3-5 The 
spontaneous course of an acutely decompensated hemangioma 
is generally unfavorable.
6
Thus, many treatment modalities for symptomatic CCH 




9-12 transpupillary thermotherapy 
(TTT),
13 and photodynamic therapy (PDT).
14-17 However, these 
treatment options may cause additional, severe functional 
impairment.
Bevacizumab (Avastin, Genentech, Inc., San Francisco, 
CA) is a humanized monoclonal antibody to vascular endo-
thelial growth factor (VEGF). Selective antibody blocking 
(anti-VEGF therapy) inhibits the formation of abnormal 
blood vessels and decreases vascular permeability.
18 In an 
off-label manner, intravitreal bevacizumab has been used to 
treat various neovascular ocular pathologies,
19,20 macular 
edema (ME),
21,22 and revision of a filtering bleb.
23 And, recent 
case studies have reported on the efficacy of bevacizumab for 
the treatment of vasoproliferative retinal tumors including 
retinal capillary hemangioma.
24,25 From these observations, 
we thought that bevacizumab should offer the ideal qualities 
for the treatment of CCH with subretinal fluid. To our know-
ledge, this is the first report to apply bevacizumab in the 
treatment of CCH.
We here report a case of recurrrent CCH with prior photo-
coagulation that improved clinically after intravitreal bevaci-
zumab and two cases of CCHs that showed visual and clinical 




A 55-year-old man was initially referred at the age of 42 
years because of decreased vision and submacular fluid that 
was thought to be related to a choroidal lesion centered 
inferior to the macula. Ophthalmic examination documented 
visual acuity of 1.0 OD and 0.3 OS. The fundus showed 
normal retina in the right eye and a pink choroidal tumor 
inferior to the macula, with accumulation of subretinal fluid 
into the macular area, in the left eye. A fluorescein angiography 
showed early preretinal patchy hyperfluorescence and patchy 
late staining of the tumor with some dye leakage into the sub-
macular space. A clinical diagnosis of circumscribed choroidal 
hemangioma with exudative detachment was made. At pre-Korean J Ophthalmol Vol.23, No.2, 2009
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Fig. 1. Case 1. (A) Recurrent choroidal hemangioma with sub-
macular fluid, previously treated by photocoagulation, before 
intravitreal bevacizumab. Ultrasonography reveals a tumor thick-
ness of 1.6 mm. Optical coherence tomography (OCT) demon-
strates the presence of submacular fluid. (B) Two months after 
intravitreal bevacizumab. The hemangioma thickness is reduced 
on ultrasonography and the subretinal fluid around the tumor is 
absorbed on OCT.
AB
Fig. 2. Case 2. (A) A red-orange choroidal hemangioma with 
submacular fluid. Fluorescein angiography shows late patchy 
staining of the tumor with some dye leakage into the submacular 
space and ultrasonography reveals a solid dome-shaped lesion 
2.4 mm in thickness. (B) Three months after bevacizumab followed 
by photodynamic therapy. The hemangioma has flattened and shows 
pigmentary change by the retinal pigment epithelium atrophy. 
Fluorescein angiography reveals marked regression of the leakage 
into the macula and some hypofluorescence caused by pigmentary 
change. The tumor has regressed to a non-measurable thickness on 
ultrasonography.
sentation, a treatment with photocoagulation to the surface of 
the lesion had been administered in an attempt to foster 
resolution of the vision-impairing subretinal fluid. Two 
months later, visual acuity had improved from 0.3 OS to 0.8 
OS and remained relatively stable for one year. Since then, 
follow-up was lost for thirteen years.
He visited again with a two-week history of decreased 
visual acuity in the same eye. The visual acuity had decreased to 
0.3 OS. Ophthalmoscopic examination of the left eye revealed 
an elevated orange-red lesion inferior to the macula, with 
localized areas of retinal pigment epithelial rarefaction and 
clumping caused by prior photocoagulation. A serous detach-
ment of edematous neurosensory retina extended from the 
lesion into the macular area. Ultrasonography revealed a dome- 
shaped choroidal tumor 1.6 mm thick with high internal 
reflectivity. Optical coherence tomography (OCT) also demon-
strated submacular fluid around the tumor.
After obtaining the patient’s fully informed consent, we 
treated the lesion with intravitreal bevacizumab injection 
(1.25 mg in 0.05 mL in a tuberculin syringe). The injection 
was performed in a sterile fashion through pars plana using a 
30-gauge needle after preparation with a topical anesthetic 
and placement of a lid speculum. Following injection, optic 
nerve perfusion was assessed by clinical examination with 
dilated ophthalmoscopy and topical antibiotics were used 
three times daily for one week.
At follow-up one month later, subretinal fluid around the 
tumor was not recognizable, and visual acuity had improved 
to 0.6 OS. Two months later, visual acuity was 1.0 OS, and 
B-scan ultrasonography showed a decrease of the tumor (Fig. 
1). The tumor had not recurred during follow-up of eight 
months.
Case 2
A 47-year-old woman was presented with a recent decrease 
in vision in her right eye. Visual acuity was 0.15 OD and 1.0 
OS. The left fundus was normal. The right fundus showed an 
elevated, red-orange choroidal lesion superotemporal to the 
macula with a thin layer of subretinal fluid into the macular 
area. B-scan ultrasonography revealed a lesion with high 
internal reflectivity measuring 2.4 mm in thickness. Fluorescein 
angiography showed prearterial patchy filling of the tumor 
with late patchy staining and dye leakage into the subretinal 
space. The patient was clinically diagnosed as a CCH.
After obtaining fully informed consent, bevacizumab (1.25 
mg in 0.05 mL in a tuberculin syringe) was injected. One 
week after the intravitreal bevacizumab, serous detachment 
had decreased and visual acuity had increased to 0.5 OD. At 
this time, PDT was administered. The patient received an M Sagong, et al. INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL HEMANGIOMA
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Fig. 3. Case 3. (A) A red-orange choroidal hemangioma conti-
guous with optic nerve from the 8-o’clock position clockwise to 
the 1-o’clock position. A serous detachment around the tumor 
extends into the macula. Fluorescein angiography shows dye 
leakage into the submacular space and optical coherence tomo-
graphy (OCT) demonstrates serous detachment around the fovea. 
(B) Three months after bevacizumab followed by photodynamic 
therapy. The tumor has flattened around the macula, without 
subretinal fluid. Fluorescein angiography shows no submacular 
leakage and diminished hyperfluorescence in the tumor. OCT 
shows nearly regular foveal anatomy.
Table 1. Patient characteristics
Case No./ Age (yr) / Sex Initial tumor
thickness (mm)








1/55/M 1.6 1.0 0.3 OS 1.0 OS 8
2/47/F 2.4 Flat 0.15 OD 0.8 OD 6
3/51/M 2.2 Flat 0.06 OD 0.3 OD 9
intravenous infusion of 6 mg/m
2 of verteporfin (Visudyne, 
Norvatis Ophthalomics, Hettlingen, Switzerland). Fifteen 
minutes after the start of the infusion (approximately five 
minutes after completion of infusion), laser light at 689 nm 
was delivered with an intensity of 600 mW/cm
2 for 83 
seconds (50 J/cm
2). The diameter of the treatment spot was 
5,200 μm which was based on the lesion size measured on the 
pretreatment fluorescein angiography. No additional safety 
margin was added to the diameter of the spot.
Two weeks after PDT, visual acuity had improved to 0.6 
OD. B-scan ultrasonography at this time showed a marked 
reduction in the thickness of the tumor. There was no subretinal 
fluid, but the primary ophthalmoscopic appearance showed 
rarefaction of the retinal pigment epithelium at the tumor 
site. Three months after PDT, visual acuity had improved to 
0.8 OD and the tumor was completely flat. However, RPE 
atrophy remained at the site of the original tumor (Fig. 2). 
There was no tumor recurrence at the six-month follow-up 
visit.
Case 3
A 51-year-old man was referred for a 10-day history of 
decreased visual acuity in the right eye. Visual acuity was 
0.06 OD and 1.0 OS. Fundus examination of the right eye 
showed an elevated, orange-red choroidal lesion that was 
contiguous with the optic nerve from approximately the 
8-o’clock position clockwise to the 1-o’clock position. There 
was a serous detachment of the sensory retina that extended 
from the tumor into the macular area. Ultrasonography revealed 
a tumor thickness of 2.2 mm. The fluorescein angiographic 
features of the lesion were characteristic of hemangioma. 
Choroidal hemangioma with vision loss from associated sub-
macular fluid was diagnosed.
After informed consent was obtained, intravitreal bevaci-
zumab (1.25 mg in 0.05 mL) was injected. One week later, a 
decrease in subretinal fluid was noted. At this time, PDT was 
performed (laser spot size of 5,100 μm) using the same power 
and intensity as described in case 2 but not overlapping the 
optic nerve with the laser.
Two weeks after PDT, subretinal fluid was absent, and 
visual acuity was 0.15 OD. Three months after PDT, visual 
acuity had improved to 0.3 OD and the tumor had markedly 
regressed (Fig. 3). Nine months after treatment, the visual 
acuity remained 0.3 OD, and no tumor had recurred.
Discussion
CCH is a benign intraocular hamartoma that can cause 
visual impairment by various mechanisms, such as transudative 
leakage, accumulation of subretinal fluid and serous retinal 
detachment with secondary photoreceptor damage as well as 
cystoids macular edema.
3-5 Treatment is required only for 
patients with visual symptoms.
3 In cases of small asymptomatic 
lesions, observation is recommended to detect any signs of 





9 external beam radiotherapy,




14-17 have been proposed for the 
treatment of symptomatic CCH. These treatments are chosen 
variably depending on tumor size, location, and associated 
subretinal fluid.
26 They have been shown to be beneficial in a 
number of cases.
However, these currently available treatments have limita-
tions because of the invasiveness, lack of effectiveness, 
complications, or lack of precision with which the lesion can 
be treated. After laser photocoagulation, leakage from heman-Korean J Ophthalmol Vol.23, No.2, 2009
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giomas have recurred in more than 50% of patients and often 
have resulted to progressive visual loss.
4,7 Radiation therapy 
or proton beam therapy may lead to complications such as 
cataract, radiation maculopathy or retinopathy, and an in-
creased risk for development of osteosarcomas or soft tissue 
sarcomas.
9-12 TTT induces chorioretinal atrophy in the treated 
area and is not beneficial in subfoveal lesions.
13 PDT may 
also cause infrequent complication such as chorioretinal atrophy 
resulting from too intensified treatment.
14,17
Meanwhile, bevacizumab has been approved for the treat-
ment of metastatic colorectal cancer. It acts as an inhibitor of 
VEGF, potentially decreasing the permeability of the retinal 
vasculature.
18 During recent years, intravitreal bevacizumab 
injection has been used in the treatment of ME associated with 
diabetic retinopathy, central retinal vein occlusion and neovas-
cular age-related macular degeneration while reporting that 
adverse effects of these injections did not show any increase 
in the rate of potential ocular and systemic events.
20-22 Other 
reports have shown intravitreal bevacizumab to be effective 
for the treatment of pseudophakic ME and radiation ME.
27,28 
With regard to management of intraocular tumor using bevaci-
zumab, Kenawy et al.
24 reported a patient with vasoproli-
ferative retinal tumor, who showed visual and clinical im-
provement after this treatment. Wang et al.
29 underlined that 
bevacizumab alone can lead to a reduction in the tumor- 
associated exudation, presumably by depleting endothelial 
fenestrae and altering intercellular adhesion molecules. On 
the basis of these observations, intravitreal bevacizumab was 
considered as an alternative to standard therapy in the first 
patient who had a small CCH with subretinal fluid recurrence 
after prior laser photocoagulation. Judging by the lack of 
complications in previous studies using intravitreal bevaci-
zumab,
18-22 the risk of adverse results in patients with CCH 
seemed low. This patient showed a marked improvement in 
visual acuity resulting from resorption of subretinal fluid and 
regression of the macular edema, which was maintained for 
eight months. Thus, we thought that bevacizumab should 
offer a new, effective approach to the treatment of CCH, even 
though the follow-up period was short and this case was a 
small tumor with recent subretinal fluid which may be con-
sidered good prognostic factor for vision recovery.
In many reports related to the management of CCH, 
treatments have been aimed primarily at decreasing tumor- 
associated leakage and subretinal fluid that cause visual 
symptoms. But, some investigators reported that an ideal 
treatment for CCH should achieve not only the regression of 
subretinal fluid, but also the occlusion of the vascular 
network of the tumor or its complete atrophy, thus inducing 
preservation, if not improvement, of the retinal function.
14-17 
And others reported that the persistence of abnormal vascular 
tissue can cause recurrence of subretinal fluid with progre-
ssive impairment of visual acuity.
6,16 PDT allows selective 
photochemical destruction through free radical induced 
damage of vascular endothelial cells, while preserving normal 
retinal and neurosensory structures. Occlusion of targeted 
abnormal vessels results in vascular tissue fibrosis and 
secondary tumor regression. Schmidt-Erfurth et al.
30 demon-
strated complete and irreversible vascular occlusion of ex-
perimental choroidal tumors after PDT. Thus, for recent 
several years, PDT has been accepted as the most effective 
treatment modality for CCH.
However, CCH is typically thicker than choroidal neo-
vascular lesions and has a distinct circulation characteristic 
showing an early well-defined area of intense hyperfluore-
scence, often followed by dye washout in late frames on indo-
cyanine green angiography.
15 The depth of vascular occlusion 
by PDT treatment depends on the total light dose delivered.
14,16 
Consequently, most studies using PDT for CCH modified 
standard protocol adapted in the treatment of age-related 
macular degeneration.
14-17 These modifications included higher 
exposure levels, bolus dye administration, and shorter time 
interval between dye infusion and laser application. In addition, 
Porrini et al.
16 reported that additional sessions of PDT were 
required to achieve complete regression in cases of thicker 
CCH. Modified PDT and multiple sessions of PDT are 
thought to increase the risk of over treatment effects, such as 
retinal ischemia or choroidal occlusion with subsequent RPE 
atrophy. Some cases of focal chorioretinal atrophy were reported 
in previous studies using a modified and intensified PDT 
protocol or multiple session of PDT.
14,16
Ziemssen et al.
25 reported a case of juxtapapillary retinal 
capillary hemangioma, successfully treated with a combination 
of intravitreal bevacizumab and PDT. The investigators 
believed that the anti-exudative effect of bevacizumab offers 
better delineation of the underlying choroidal lesion and 
consequently allows more precise adjustment of the PDT to 
minimize complications such as transient visual disturbance 
and chorioretinal atrophy.
25 Therefore, we considered combi-
nation therapy with intravitreal bevacizumab (1.25 mg) and 
PDT (verteporfin 6 mg/m
2 over 10 minutes, a radiant expo-
sure of 50 J/cm
2 with an exposure time of 83 seconds) in the 
second and third patients who had thicker CCHs. Combi-
nation therapy induced marked tumor regression and improved 
visual acuity resulting from disappearance of the subretinal 
fluid. However, the second patient had focal chorioretinal 
atrophy in the lesion treated with PDT. It is thought that beva-
cizumab decreases the tumor thickness through resorption of 
subretinal fluid, and this may increase the irradiation dose 
delivered by PDT. Thus, further studies on the optimal reduced 
dose of PDT are still needed to minimize PDT-associated 
complications in combination therapy.
In summary, intravitreal bevacizumab showed encouraging 
effect to increase visual acuity through inducing resorption of 
subretinal fluid associated with CCH. Bevacizumab therapy 
combined with PDT achieved marked atrophy of the tumor 
with reducing the necessity of further destruction by repeated 
and overdosed PDT. Therefore, we believe that intravitreal 
bevacizumab may be considered as a new treatment modality 
in patients with thin CCH and the combination therapy can 
be chosen as more effective treatment to decrease the risk of M Sagong, et al. INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL HEMANGIOMA
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PDT-associated complications in patients with thick CCH 
than PDT alone.
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